Related Experiment Videos
Cholesterol embolization syndrome. Occurrence after intravenous streptokinase therapy for myocardial infarction
1Department of Medicine, Veterans Administration Medical Center, Seattle, WA 98108.
Insights
Cholesterol embolization syndrome can occur after procedures like coronary angiography and streptokinase therapy for heart attacks. This serious condition involves organ damage and can lead to kidney failure or death.
Area of Science:
- Cardiology
- Nephrology
- Vascular Medicine
Background:
- Acute myocardial infarction (AMI) management often involves interventions like coronary angiography.
- Thrombolytic therapy, such as intravenous streptokinase, is used to treat AMI.
- Atherosclerosis poses risks during cardiovascular interventions.
Observation:
- Two patients experienced cholesterol embolization syndrome (CES) post-coronary angiography and streptokinase therapy.
- Clinical signs included cyanosis, ulcers, gangrene, myalgias, intestinal infarction, eosinophilia, and renal failure.
- One patient expired, while the other developed chronic renal failure.
Findings:
- Streptokinase therapy may promote CES by lysing thrombi, potentially dislodging atheromatous plaques.
- The syndrome presents with multi-organ ischemic manifestations.
- Renal involvement is a significant complication.
Implications:
- Physicians should consider CES in patients with risk factors undergoing angiography and thrombolysis.
- Early recognition and management of CES are crucial for patient outcomes.
- Further research into the mechanism of plaque embolization during thrombolysis is warranted.
Abstract:
Two patients developed the cholesterol embolization syndrome after coronary angiography and intravenous streptokinase therapy for acute myocardial infarction. Clinical manifestations included cyanosis, ulcers, gangrene of the hands and feet, myalgias, intestinal infarction, eosinophilia, and renal failure. One patient died; one has survived with chronic renal failure. Streptokinase therapy may expose atheromatous plaques to the circulation by lysing platelet-fibrin thrombi.